查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球药品监管事务市场研究报告 - 2023 年至 2030 年产业分析、规模、份额、成长、趋势与预测
市场调查报告书
商品编码
1377862

全球药品监管事务市场研究报告 - 2023 年至 2030 年产业分析、规模、份额、成长、趋势与预测

Global Pharmaceutical Regulatory Affairs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 235 Pages | 商品交期: 最快1-2个工作天内

价格

全球药品监管事务市场需求预计将从 2022 年的 92.3 亿美元增至 2030 年近 176 亿美元，2023-2030 年研究期间CAGR为 8.4%。

药品监管事务，在製药行业中通常简称为监管事务 (RA)，是一项关键职能，负责确保製药和生物技术公司遵守管理开发、製造、测试、营销和分销的所有相关法规和法律。药品和医疗产品。该领域在将安全有效的药物和医疗保健产品推向市场方面发挥核心作用，同时确保它们在整个生命週期中始终符合监管标准。

市场动态：

製药监管事务市场受到几个关键因素的推动，这些因素反映了製药业及其监管环境的动态性质。不断变化的药物开发和行销规则和要求要求製药和生物技术公司内部拥有强大的监管事务职能。药物开发的全球化、新药和疗法的不断出现以及对安全和品质标准的严格重视是关键驱动因素。生物药物、生物相似药和仿製药的兴起带来了独特的监管挑战，需要专业知识来应对复杂的审批流程。监管事务专业人员协助适应技术进步、解决 COVID-19 大流行等全球健康问题，并确保资料透明度和合规性。医疗改革、专利到期以及以患者为中心的方法的发展进一步强调了监管事务在製药运营中的重要性。这些因素共同强调了监管事务在指导製药公司应对复杂的监管环境、确保药物和疗法安全、有效并符合全球多样化和不断发展的法规方面的关键作用。随着产业不断发展和扩张，监管事务部始终处于製药成功和创新的最前线。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球药品监管事务市场的各个细分市场进行了包容性评估。药品监管事务产业的成长和趋势为本研究提供了整体方法。

区域分析：

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲药品监管事务市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。药品监管事务市场的主要参与者包括 Freyr、IQVIA Inc.、ICON plc、药明康德、Charles River Laboratories、Labcorp Drug Development、Parexel International Corporation、Pharmalex GmbH、Pharmexon、Genpact。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法论
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：药品监管事务 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按服务分類的市场吸引力分析
    • 按类别分類的市场吸引力分析
    • 按指标进行的市场吸引力分析
    • 按产品阶段分類的市场吸引力分析
    • 服务提供者的市场吸引力分析
    • 按公司规模分類的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球药品监理事务市场分析：依服务分类

  • 按服务概览
  • 历史和预测数据
  • 按服务分析
  • 监理咨询
  • 法律代表
  • 监理写作与出版（写作、出版）
  • 产品註册及临床试验申请
  • 其他服务

第 6 章：全球药品监管事务市场分析：依类别

  • 按类别概述
  • 历史和预测数据
  • 按类别分析
  • 药物（创新药、仿製药）
  • 生物製剂（生物技术、ATMP、生物相似药）

第 7 章：全球药品监理事务市场分析：依适应症分类

  • 按适应症概述
  • 历史和预测数据
  • 按指标分析
  • 肿瘤学
  • 神经病学
  • 心臟病学
  • 免疫学
  • 其他的

第 8 章：全球药品监理事务市场分析：依产品阶段

  • 按产品阶段分類的概述
  • 历史和预测数据
  • 按产品阶段分析
  • 临床前
  • 临床研究
  • 聚甲基丙烯酸甲酯

第 9 章：全球药品监理事务市场分析：依服务提供者分类

  • 服务提供者概览
  • 历史和预测数据
  • 按服务提供者分析
  • 内部
  • 外包

第 10 章：全球药品监管事务市场分析：依公司规模

  • 按公司规模分類的概览
  • 历史和预测数据
  • 按公司规模分析
  • 小的
  • 中等的
  • 大的

第 11 章：全球药品监管事务市场分析：依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区国家/地区销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 12 章：药品监理事务公司的竞争格局

  • 药品监理事务市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 13 章：公司简介

  • 公司股份分析
  • 市场集中度
  • Freyr
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • IQVIA Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • ICON plc
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • WuXi AppTec
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Charles River Laboratories
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Labcorp Drug Development
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Parexel International Corporation
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Pharmalex GmbH
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Pharmexon
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Genpact
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

Product Code: VMR112112255

The global demand for Pharmaceutical Regulatory Affairs Market is presumed to reach the market size of nearly USD 17.6 BN by 2030 from USD 9.23 BN in 2022 with a CAGR of 8.4% under the study period 2023 - 2030.

Pharmaceutical regulatory affairs, often simply referred to as Regulatory Affairs (RA) in the pharmaceutical industry, is a critical function responsible for ensuring that pharmaceutical and biotechnology companies comply with all relevant regulations and laws governing the development, manufacturing, testing, marketing, and distribution of drugs and medical products. This field plays a central role in bringing safe and effective medications and healthcare products to market while ensuring that they remain in compliance with regulatory standards throughout their lifecycle.

MARKET DYNAMICS:

The Pharmaceutical regulatory affairs market is propelled by several critical factors that reflect the dynamic nature of the pharmaceutical industry and its regulatory landscape. The ever-changing rules and requirements governing drug development and marketing necessitate a robust Regulatory Affairs function within pharmaceutical and biotechnology companies. Globalization of drug development, the continuous emergence of new drugs and therapies, and the stringent emphasis on safety and quality standards are key drivers. The rise of biologic drugs, biosimilars, and generic medications presents unique regulatory challenges that demand expertise in navigating complex approval processes. Regulatory Affairs professionals assist in adapting to technological advances, addressing global health concerns like the COVID-19 pandemic, and ensuring data transparency and compliance. Healthcare reforms, patent expirations, and the growth of patient-centric approaches further underscore the significance of Regulatory Affairs in pharmaceutical operations. These factors collectively underscore the critical role of Regulatory Affairs in guiding pharmaceutical companies through the intricate regulatory landscape, ensuring that drugs and therapies are safe, effective, and compliant with diverse and evolving regulations worldwide. As the industry continues to evolve and expand, Regulatory Affairs remains at the forefront of pharmaceutical success and innovation.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pharmaceutical regulatory affairs. The growth and trends of pharmaceutical regulatory affairs industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the pharmaceutical regulatory affairs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Services

  • Regulatory Consulting
  • Legal Representation
  • Regulatory Writing & Publishing (Writing, Publishing)
  • Product Registration & Clinical Trial Applications
  • Other Services

By Category

  • Drugs (Innovator, Generics)
  • Biologics (Biotech, ATMP, Biosimilars)

By Indication

  • Oncology
  • Neurology
  • Cardiology
  • Immunology
  • Others

By Product Stage

  • Preclinical
  • Clinical Studies
  • PMA

By Service Provider

  • In-House
  • Outsourcing

By Company Size

  • Small
  • Medium
  • Large

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Pharmaceutical Regulatory Affairs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pharmaceutical Regulatory Affairs market include Freyr, IQVIA Inc., ICON plc, WuXi AppTec, Charles River Laboratories, Labcorp Drug Development, Parexel International Corporation, Pharmalex GmbH, Pharmexon, Genpact. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . PHARMACEUTICAL REGULATORY AFFAIRS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Services
    • 3.7.2 Market Attractiveness Analysis By Category
    • 3.7.3 Market Attractiveness Analysis By Indication
    • 3.7.4 Market Attractiveness Analysis By Product Stage
    • 3.7.5 Market Attractiveness Analysis By Service Provider
    • 3.7.6 Market Attractiveness Analysis By Company Size
    • 3.7.7 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY SERVICES

  • 5.1 Overview by Services
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Services
  • 5.4 Regulatory Consulting Historic and Forecast Sales by Regions
  • 5.5 Legal Representation Historic and Forecast Sales by Regions
  • 5.6 Regulatory Writing & Publishing (Writing, Publishing) Historic and Forecast Sales by Regions
  • 5.7 Product Registration & Clinical Trial Applications Historic and Forecast Sales by Regions
  • 5.8 Other Services Historic and Forecast Sales by Regions

6 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY CATEGORY

  • 6.1 Overview by Category
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Category
  • 6.4 Drugs (Innovator, Generics) Historic and Forecast Sales by Regions
  • 6.5 Biologics (Biotech, ATMP, Biosimilars) Historic and Forecast Sales by Regions

7 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY INDICATION

  • 7.1 Overview by Indication
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Indication
  • 7.4 Oncology Historic and Forecast Sales by Regions
  • 7.5 Neurology Historic and Forecast Sales by Regions
  • 7.6 Cardiology Historic and Forecast Sales by Regions
  • 7.7 Immunology Historic and Forecast Sales by Regions
  • 7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY PRODUCT STAGE

  • 8.1 Overview by Product Stage
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Product Stage
  • 8.4 Preclinical Historic and Forecast Sales by Regions
  • 8.5 Clinical studies Historic and Forecast Sales by Regions
  • 8.6 PMA Historic and Forecast Sales by Regions

9 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY SERVICE PROVIDER

  • 9.1 Overview by Service Provider
  • 9.2 Historical and Forecast Data
  • 9.3 Analysis by Service Provider
  • 9.4 In-house Historic and Forecast Sales by Regions
  • 9.5 Outsourcing Historic and Forecast Sales by Regions

10 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY COMPANY SIZE

  • 10.1 Overview by Company Size
  • 10.2 Historical and Forecast Data
  • 10.3 Analysis by Company Size
  • 10.4 Small Historic and Forecast Sales by Regions
  • 10.5 Medium Historic and Forecast Sales by Regions
  • 10.6 Large Historic and Forecast Sales by Regions

11 . GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY GEOGRAPHY

  • 11.1. Regional Outlook
  • 11.2. Introduction
  • 11.3. North America Sales Analysis
    • 11.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 11.3.2. North America By Segment Sales Analysis
    • 11.3.3. North America By Country Sales Analysis
    • 11.3.4. United State Sales Analysis
    • 11.3.5. Canada Sales Analysis
    • 11.3.6. Mexico Sales Analysis
  • 11.4. Europe Sales Analysis
    • 11.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 11.4.2. Europe by Segment Sales Analysis
    • 11.4.3. Europe by Country Sales Analysis
    • 11.4.4. United Kingdom Sales Analysis
    • 11.4.5. France Sales Analysis
    • 11.4.6. Germany Sales Analysis
    • 11.4.7. Italy Sales Analysis
    • 11.4.8. Russia Sales Analysis
    • 11.4.9. Rest Of Europe Sales Analysis
  • 11.5. Asia Pacific Sales Analysis
    • 11.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 11.5.2. Asia Pacific by Segment Sales Analysis
    • 11.5.3. Asia Pacific by Country Sales Analysis
    • 11.5.4. China Sales Analysis
    • 11.5.5. India Sales Analysis
    • 11.5.6. Japan Sales Analysis
    • 11.5.7. South Korea Sales Analysis
    • 11.5.8. Australia Sales Analysis
    • 11.5.9. South East Asia Sales Analysis
    • 11.5.10. Rest Of Asia Pacific Sales Analysis
  • 11.6. Latin America Sales Analysis
    • 11.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 11.6.2. Latin America by Segment Sales Analysis
    • 11.6.3. Latin America by Country Sales Analysis
    • 11.6.4. Brazil Sales Analysis
    • 11.6.5. Argentina Sales Analysis
    • 11.6.6. Peru Sales Analysis
    • 11.6.7. Chile Sales Analysis
    • 11.6.8. Rest of Latin America Sales Analysis
  • 11.7. Middle East & Africa Sales Analysis
    • 11.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 11.7.2. Middle East & Africa by Segment Sales Analysis
    • 11.7.3. Middle East & Africa by Country Sales Analysis
    • 11.7.4. Saudi Arabia Sales Analysis
    • 11.7.5. UAE Sales Analysis
    • 11.7.6. Israel Sales Analysis
    • 11.7.7. South Africa Sales Analysis
    • 11.7.8. Rest Of Middle East And Africa Sales Analysis

12 . COMPETITIVE LANDSCAPE OF THE PHARMACEUTICAL REGULATORY AFFAIRS COMPANIES

  • 12.1. Pharmaceutical Regulatory Affairs Market Competition
  • 12.2. Partnership/Collaboration/Agreement
  • 12.3. Merger And Acquisitions
  • 12.4. New Product Launch
  • 12.5. Other Developments

13 . COMPANY PROFILES OF PHARMACEUTICAL REGULATORY AFFAIRS INDUSTRY

  • 13.1. Company Share Analysis
  • 13.2. Market Concentration Rate
  • 13.3. Freyr
    • 13.3.1. Company Overview
    • 13.3.2. Company Revenue
    • 13.3.3. Products
    • 13.3.4. Recent Developments
  • 13.4. IQVIA Inc.
    • 13.4.1. Company Overview
    • 13.4.2. Company Revenue
    • 13.4.3. Products
    • 13.4.4. Recent Developments
  • 13.5. ICON plc
    • 13.5.1. Company Overview
    • 13.5.2. Company Revenue
    • 13.5.3. Products
    • 13.5.4. Recent Developments
  • 13.6. WuXi AppTec
    • 13.6.1. Company Overview
    • 13.6.2. Company Revenue
    • 13.6.3. Products
    • 13.6.4. Recent Developments
  • 13.7. Charles River Laboratories
    • 13.7.1. Company Overview
    • 13.7.2. Company Revenue
    • 13.7.3. Products
    • 13.7.4. Recent Developments
  • 13.8. Labcorp Drug Development
    • 13.8.1. Company Overview
    • 13.8.2. Company Revenue
    • 13.8.3. Products
    • 13.8.4. Recent Developments
  • 13.9. Parexel International Corporation
    • 13.9.1. Company Overview
    • 13.9.2. Company Revenue
    • 13.9.3. Products
    • 13.9.4. Recent Developments
  • 13.10. Pharmalex GmbH
    • 13.10.1. Company Overview
    • 13.10.2. Company Revenue
    • 13.10.3. Products
    • 13.10.4. Recent Developments
  • 13.11. Pharmexon
    • 13.11.1. Company Overview
    • 13.11.2. Company Revenue
    • 13.11.3. Products
    • 13.11.4. Recent Developments
  • 13.12. Genpact
    • 13.12.1. Company Overview
    • 13.12.2. Company Revenue
    • 13.12.3. Products
    • 13.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Services (USD MN)
  • Regulatory Consulting Market Sales by Geography (USD MN)
  • Legal Representation Market Sales by Geography (USD MN)
  • Regulatory Writing & Publishing (Writing, Publishing) Market Sales by Geography (USD MN)
  • Product Registration & Clinical Trial Applications Market Sales by Geography (USD MN)
  • Other Services Market Sales by Geography (USD MN)
  • Analysis Market by Category (USD MN)
  • Drugs (Innovator, Generics) Market Sales by Geography (USD MN)
  • Biologics (Biotech, ATMP, Biosimilars) Market Sales by Geography (USD MN)
  • Analysis by Indication (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Neurology Market Sales by Geography (USD MN)
  • Cardiology Market Sales by Geography (USD MN)
  • Immunology Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis by Product Stage (USD MN)
  • Preclinical Market Sales by Geography (USD MN)
  • Clinical studies Market Sales by Geography (USD MN)
  • PMA Market Sales by Geography (USD MN)
  • Analysis by Service Provider (USD MN)
  • In-house Market Sales by Geography (USD MN)
  • Outsourcing Market Sales by Geography (USD MN)
  • Analysis by Company Size (USD MN)
  • Small Market Sales by Geography (USD MN)
  • Medium Market Sales by Geography (USD MN)
  • Large Market Sales by Geography (USD MN)
  • Global Pharmaceutical Regulatory Affairs Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Pharmaceutical Regulatory Affairs Report
  • Market Research Process
  • Market Research Methodology
  • Global Pharmaceutical Regulatory Affairs Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Services
  • Market Attractiveness Analysis by Category
  • Market Attractiveness Analysis by Indication
  • Market Attractiveness Analysis by Product Stage
  • Market Attractiveness Analysis by Service Provider
  • Market Attractiveness Analysis by Company Size
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Services (USD MN)
  • Regulatory Consulting Market Sales by Geography (USD MN)
  • Legal Representation Market Sales by Geography (USD MN)
  • Regulatory Writing & Publishing (Writing, Publishing) Market Sales by Geography (USD MN)
  • Product Registration & Clinical Trial Applications Market Sales by Geography (USD MN)
  • Other Services Market Sales by Geography (USD MN)
  • Global Market Analysis by Category (USD MN)
  • Drugs (Innovator, Generics) Market Sales by Geography (USD MN)
  • Biologics (Biotech, ATMP, Biosimilars) Market Sales by Geography (USD MN)
  • Global Market Analysis by Indication (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Neurology Market Sales by Geography (USD MN)
  • Cardiology Market Sales by Geography (USD MN)
  • Immunology Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Product Stage (USD MN)
  • Preclinical Market Sales by Geography (USD MN)
  • Clinical studies Market Sales by Geography (USD MN)
  • PMA Market Sales by Geography (USD MN)
  • Global Market Analysis by Service Provider (USD MN)
  • In-house Market Sales by Geography (USD MN)
  • Outsourcing Market Sales by Geography (USD MN)
  • Global Market Analysis by Company Size (USD MN)
  • Small Market Sales by Geography (USD MN)
  • Medium Market Sales by Geography (USD MN)
  • Large Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.